The FDA and prescription benefits manager Medco Health Solutions have entered into a two-year agreement to study pharmacogenomics. Using reports produced by Medco based on the pharmacy claims of its 60 million members, FDA will assess the use of genetic tests for prescribing drugs and determining drug safety, as well as how doctors utilize such tests. The first targets of the study are likely to be oncology and HIV/AIDS, but will not be determined until the fall. Medco plans to publish the study’s results in a peer-reviewed journal. Medco is also collaborating with the Mayo Clinic on a study of the blood thinner warfarin and with Laboratory Corporation on a study of tamoxifen, a treatment for breast cancer. Source: Reuters